C. Casini Raggi

This paper describes engineered liver tissue that reverses acute liver failure in mice without immunosuppression, demonstrating potential for clinical translation.

This study identifies the minimal effective NTBC dose to prevent liver damage in HT1 using an in vitro model and validates it in 99 patients, while highlighting residual gene dysregulation linked to cancer risk.